All PlansCoverageLow impact
Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Pulmonology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes coverage criteria for proteomic testing (such as VeriStrat assay) to predict treatment response and select targeted therapy for non-small-cell lung cancer patients. The policy provides detailed background on NSCLC treatment options and genetic testing but does not specify clear coverage determinations or billing requirements.
Action Required
Review policy document for specific coverage criteria and billing requirements for proteomic testing in NSCLC patients. Monitor for additional policy updates that may include specific CPT codes, prior authorization requirements, or coverage determinations for VeriStrat and similar proteomic assays.